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letters to the editor 443
all cases of CDI with onset during hospitalization or within
72 hours after patient discharge. We subsequently undertook
a search of all microbiologically confirmed cases of CDI dur-
ing the period 2007–2012. Individuals who shared the same
surname or same address were identified for additional in-
vestigation. All putative case-pairs identified were reviewed
to identify potential epidemiological associations; this in-
cluded ribotyping of available C. difficile isolates and, when
possible, multiple-locus variable number tandem repeat anal-
ysis (MLVA). Six cases of paired CDI were identified.
In pair 1, the index patient, a 74-year-old woman, was
admitted for investigation and management of diarrhea. She
had had an episode of CDI earlier that year and received a
diagnosis of recurrent CDI during this hospitalization. A
specimen obtained within 1 day of admission to the hospital
was found to be positive for glutamate dehydrogenase (GDH)
and C. difficile toxin. One week later, the patient’s husband
(also her main caregiver) developed CDI. The contact patient
had multiple comorbidities and his own independent risk
factors for CDI. Isolates from both patients were identified
as ribotype 027, and they were indistinguishable on MVLA
typing.
In pair 2, the index patient, a 76-year-old woman, was
admitted to the hospital for investigation of suspected acute
colitis after chemotherapy. A stool sample obtained at hospital
admission was found to be positive for GDH but negative
for C. difficile toxin, which suggested C difficile colonization
rather than CDI. However, because of persistent symptoms,
the patient was given metronidazole therapy, to which she
responded well. Her husband, a patient with chronic lung
disease who required recurrent antibiotic therapy for infective
exacerbations in the community, was admitted to the hospital
10 days later with diarrhea. A stool sample obtained the fol-
lowing day was positive for both GDH and C. difficile toxin.
Both isolates belonged to ribotype 127.
In pair 3, a 39-year-old woman received a diagnosis of CDI
in the community after receiving antibiotic therapy for pre-
sumed cholecystitis. Her 15-month-old son presented to his
primary care physician with diarrhea. At the family’s request,
a stool sample was tested and was found to be positive for
both GDH and C. difficile toxin. Ribotyping of the isolates
demonstrated that both belonged to ribotype 017.
Review of the paired cases of CDI, taken together with
indistinguishable ribotypes and their temporal association, is
highly suggestive of an epidemiological link and thus high-
lights the potential for spread within families. Interestingly,
2 of 3 contact patients had their own independent risk factors
for CDI. In addition, the apparent transmission from a GDH-
positive but toxin-negative patient to her spouse, who went
on to develop active CDI, is also of particular note. Although
the clinical significance of isolating C. difficile in an infant is
not clear, as in the last case-pair, the matching ribotypes
suggest a putative link between the 2 cases.
A recent study has suggested that intrafamilial transmission
of CDI is infrequent.1 Our findings corroborate this. We iden-
tified 3 case-pairs from a total of 238 confirmed cases of CDI
over a 5-year period. However, the database search relied on
identification of shared surname and address, and this may
have underestimated the frequency of transmission. Never-
theless, we have amended the information on CDI given to
patients and their relatives. In particular, we have reinforced
the importance of adopting appropriate hand hygiene mea-
sures by index case patients and family members (both at
home and in the hospital) in an attempt to reduce the risk
of intrafamilial spread of CDI.
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East North Central Region Has the Highest
Prevalence of Vancomycin-Resistant
Enterococcus faecalis in the United States
To the Editor—We read the article of Hayakawa et al1 with
great interest. The report describes the growing prevalence
of vancomycin-resistant Enterococcus faecalis in Michigan, a
state that also has the most reports of vancomycin-resistant
Staphylococcus aureus. Similar findings were reported in the
tigecycline evaluation and surveillance trial (TEST).2 During
the 2004–2009 period, 4.6% of 3,753 E. faecalis isolates were
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figure 1. Proportion of vancomycin-resistant Enterococcus faecalis in the United States by region. The Midwest census region was split
into the West North Central and East North Central divisions to highlight the higher prevalence of resistance among isolates from the
latter.
vancomycin resistant, with the highest rates of 7.6% in the
East North Central region of United States. Here we report
rates and trends of vancomycin-resistant E. faecalis in the East
North Central region compared with national rates from 1999
to 2010.
The antimicrobial susceptibility data were obtained from
the Surveillance Network Database (Eurofins-Medinet). The
data are described in detail elsewhere3 and have been widely
used to characterize regional and national trends in antibiotic
susceptibility.4-7 The 287 microbiological laboratories in the
network were selected on the basis of geographic and de-
mographic criteria to be representative of hospitals at the level
of US Census Bureau regional divisions. Participating sites
are required to submit reports for all bacterial isolates for
which species identification and antibiotic sensitivities are
recorded. Categorical susceptibility results are based on the
Clinical Laboratory Standards Institute criteria adopted by
the facility at the time of testing and reflect results as they
were reported to the treating physician.
The analysis considered all outpatient and inpatient (in-
cluding inpatient, outpatient, intensive care unit, and long-
term care) isolates reported between January 1999 and July
2010 that were identified as E. faecalis. Perirectal surveillance
cultures were not included in the database, and the data were
filtered to retain only isolates that were tested to vancomycin.
We then looked at the national and regional proportion of
isolates that were reported as resistant to vancomycin
throughout the study period.
Overall, in the East North Central region, a total of 44,108
isolates of E. faecalis between 1999 and 2010 were tested to
vancomycin, of which 8.8% ( ) were resistant ton p 3,858
vancomycin. At the national level, the pooled proportion of
vancomycin-resistant E. faecalis for 1999–2010 was 3.6%
(13,022 of 354,462 E. faecalis isolates). The Northeast region
was behind the East North Central region, with 5.2% of the
E. faecalis isolates resistant to vancomycin (for yearly national
and regional trends, see Figure 1). Figure 1 also indicates a
steady rise in the proportion of vancomycin-resistant E. fae-
calis isolates in the United States, from 2.7% in 1999 to 3.9%
in 2010.
Even though our results do not indicate a continuous rise
in the proportion of vancomycin-resistant E. faecalis isolates
from 1999 to 2010 in the East North Central region, the
regional proportions have always been high compared with
the national average. The proportion of vancomycin-resistant
E. faecalis isolates in this region remained twice the national
average during the 1999–2010 period. Eight of the 13 cases
of vancomycin-resistant S. aureus were reported from south-
east Michigan, an area approximately at the center of this
region.8 Coupled with evidence of the horizontal transfer of
the vanA gene complex from vancomycin-resistant E. faecalis
to S. aureus,9,10 our findings underscore the importance of
monitoring the trends in vancomycin-resistant E. faecalis
through continuous and timely surveillance.
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Intensified Infection Control Measures to
Minimize the Spread of Colistin-Resistant
Acinetobacter baumannii
To the Editor—The emergence of carbapenem-resistant gram-
negative bacteria (GNB) is an increasing source of healthcare-
associated infection worldwide and has been associated with
adverse clinical outcomes and resource consumption.1,2 The
use of colistin and polymixin B has been resurrected during
the past decade, especially in combination drug regimens
targeting carbapenem-resistant GNB.3 To date, the emergence
of colistin-resistant GNB has been uncommon, yet it is of
global concern.3 We report a case of pneumonia due to
colistin-resistant Acinetobacter baumannii infection in a pa-
tient who presented to an intensive care unit (ICU), imple-
mentation of intensified infection prevention control (IPC)
measures, and the ICU monitoring efforts associated with
ensuring that there was no subsequent detection of this path-
ogen in other patients. On September 15, 2012, a 74-year-
old man with chronic obstructive pulmonary disease, dia-
betes, renal failure, and recurrent carbapenem-resistant A.
baumanniii pneumonia (3 episodes in the previous 12
months) was readmitted to the medical ICU with fever, short-
ness of breath, and pneumonia. Because of a history of
carbapenem-resistant A. baumannii infection treated with co-
listin and cefoperazone-sulbactam, the patient was placed un-
der isolation precautions at hospital admission. Sputum cul-
tures obtained at admission grew colistin-resistant A.
baumannii (colistin minimum inhibitory concentration, 128
mg/mL), the infection control team was notified, and IPC
measures in the 8-bed medical ICU were initiated. The IPC
measures included (i) implementation of enhanced contact
isolation precautions (ie, strict adherence to hand hygiene
protocols before and after patient care and use of gowns and
gloves); (ii) active surveillance cultures, defined as culture of
rectal swab samples and tracheal aspirates (if the patient re-
ceived mechanical ventilation), for all patients in the unit (on
day 0, day 7, and every week until hospital discharge); (iii)
daily environmental cleaning with detergents and with phe-
nolic agents of high-touch surfaces and sites contaminated
with body fluids or with blood; (iv) an up-to-date education
program for all healthcare workers (HCWs) within the first
week of the case detection4,5; and (v) delivery of real-time
feedback to HCWs regarding IPC compliance. A case patient
was defined as a patient with nosocomial colonization or
infection with colistin-resistant A. baumannii identified by
clinical culture more than 48 hours after ICU admission;
nosocomial acquisition of this microorganism was defined as
a positive active surveillance culture more than 48 hours after
admission if the initial surveillance cultures were negative.
Active surveillance cultures were performed on tracheal as-
pirate specimens and rectal swab specimens (if the initial
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